Update on Myositis Therapy: From Today's Standards to Tomorrow's Possibilities.
Curr Pharm Des
; 28(11): 863-880, 2022.
Article
em En
| MEDLINE
| ID: mdl-34781868
ABSTRACT
Inflammatory myopathies, in short, myositis, are heterogeneous disorders that are characterized by inflammation of skeletal muscle and weakness of arms and legs. Research over the past few years has led to a new understanding regarding the pathogenesis of myositis. The new insights include different pathways of the innate and adaptive immune response during the pathogenesis of myositis. The importance of non-inflammatory mechanisms such as cell stress and impaired autophagy has been recently described. New target-specific drugs for myositis have been developed and are currently being tested in clinical trials. In this review, we discuss the mechanisms of action of pharmacological standards in myositis and provide an outlook of future treatment approaches.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Miosite de Corpos de Inclusão
/
Dermatomiosite
/
Miosite
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Curr Pharm Des
Assunto da revista:
FARMACIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Alemanha